To evaluate the INFLAME-MI score as a novel risk stratification tool incorporating inflammatory biomarkers for patients with acute coronary syndromes (ACS), highlighting its potential impact on clinical decision-making.
Key Findings:
INFLAME-MI showed good discriminatory performance (AUC 0.88 and 0.92) and excellent calibration compared to GRACE, addressing GRACE's limitations in risk estimation.
INFLAME-MI provided greater net benefit than GRACE in low-to-intermediate risk groups.
The model was derived from a single-centre cohort and validated in a small population, indicating a need for larger studies to confirm its efficacy.
Interpretation:
INFLAME-MI integrates inflammatory biomarkers into risk assessment, potentially enhancing clinical decision-making for ACS patients, especially those not requiring immediate revascularization, thus addressing a critical gap in current practices.
Limitations:
The model requires independent validation before routine clinical use, particularly due to concerns about overfitting from a small validation population.
Derived from a single-centre cohort with a small validation population, raising concerns about overfitting and generalizability.
Did not demonstrate statistical superiority in discrimination compared to GRACE, which should be noted in clinical discussions.
Conclusion:
INFLAME-MI represents a promising advancement in risk stratification for ACS, complementing existing models by incorporating biological factors, but further validation studies are essential.
Patients with lower nonischemic resting full-cycle ratio values had more repeat revascularizations despite similar 2-year major cardiovascular event rates.
